Afatinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring active EGFR mutations : an open-label, randomized, multicenter, phase II study
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Jun 2019 Status changed from recruiting to discontinued.
- 15 Sep 2017 Status changed from not yet recruiting to recruiting.
- 21 Jun 2017 New trial record